Athenex Inc.

The firm represented Athenex, Inc., a publicly traded global oncology-focused biopharmaceutical company dedicated to the discovery, development, and commercialization of novel cell therapies for the treatment of cancer, aiming to develop safer and more efficacious cancer medication with over forty affiliates located in the U.S., Asia, South America, and Europe. The firm assisted the debtors in selling substantially all of their assets through an orderly disposition process, including an active auction with several rounds of overbidding, which resulted in the sales of major operating divisions. bankruptcy, The debtors confirmed a plan of liquidation in 121 days.

Our website uses cookies to enhance site navigation, analyze site usage, and assist in our marketing efforts. By continuing to browse this website, you agree to our Privacy Policy.